Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364662 | 1.00 | EGFR (0.58) | EGFRERBB2MAOBJAK3FGFR1 | |
| SCHEMBL23902638 | 0.89 | EGFR (0.51) | EGFRERBB2MAOBFGFR1FGFR4 | |
| SCHEMBL30364613 | 0.89 | EGFR (0.51) | EGFRERBB2MAOBFGFR1FGFR4 | |
| SCHEMBL30241481 | 0.85 | ERBB2 (0.60) | EGFRERBB2MAOBFGFR1FGFR4 | |
| SCHEMBL23902645 | 0.85 | ERBB2 (0.60) | EGFRERBB2MAOBFGFR1FGFR4 | |
| SCHEMBL23902656 | 0.84 | EGFR (0.58) | EGFRERBB2MAOBJAK3FGFR1 | |
| SCHEMBL30241436 | 0.84 | EGFR (0.58) | EGFRERBB2MAOBJAK3FGFR1 | |
| SCHEMBL23902694 | 0.84 | EGFR (0.58) | EGFRERBB2MAOBJAK3FGFR1 | |
| SCHEMBL30241492 | 0.84 | EGFR (0.58) | EGFRERBB2MAOBJAK3FGFR1 | |
| SCHEMBL23902689 | 0.84 | EGFR (0.58) | EGFRERBB2MAOBFGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | claimed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | claimed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | claimed |
| EP-3892614-A1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2021-10-13 | — | — | EP | claimed |
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | disclosed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | disclosed |
| EP-3892614-A1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2021-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | YAP1, YES1, TEAD1 | EGFR 447/4885ERBB2 416/4885MAOB 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.